SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 199.07-3.4%Nov 20 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (19371)4/21/1998 8:04:00 PM
From: John O'Neill  Read Replies (4) of 32384
 
Henry, I saw 20/20 last nite & they mentioned Evista by name
as possible tx for breast CA. The also mentioned other drugs in the
pipeline (not by name) I was surprised to hear Evista for this application.

Do yoy think and RXR receptor drug like Targretin will prove most valuable as adjunct tx to Evista or by itself.

I spoke with medical staff at Ligand today...they are looking to the off lable for two upcoming NDA's....as real sales potential

They complained about you because you are right 90% of the time but completely wrong the other 10 % (:>)

JO
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News